Compare Novartis with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs IPCA LABS - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS IPCA LABS NOVARTIS/
IPCA LABS
 
P/E (TTM) x 518.8 23.5 2,208.1% View Chart
P/BV x 29.1 4.5 646.6% View Chart
Dividend Yield % 1.5 0.3 563.5%  

Financials

 NOVARTIS   IPCA LABS
EQUITY SHARE DATA
    NOVARTIS
Mar-19
IPCA LABS
Mar-19
NOVARTIS/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs9801,042 94.0%   
Low Rs600590 101.7%   
Sales per share (Unadj.) Rs198.7298.6 66.5%  
Earnings per share (Unadj.) Rs21.035.0 59.9%  
Cash flow per share (Unadj.) Rs22.349.4 45.0%  
Dividends per share (Unadj.) Rs10.003.00 333.3%  
Dividend yield (eoy) %1.30.4 344.3%  
Book value per share (Unadj.) Rs307.5247.1 124.4%  
Shares outstanding (eoy) m24.69126.35 19.5%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x4.02.7 145.5%   
Avg P/E ratio x37.723.3 161.6%  
P/CF ratio (eoy) x35.516.5 215.1%  
Price / Book Value ratio x2.63.3 77.8%  
Dividend payout %47.78.6 556.4%   
Avg Mkt Cap Rs m19,508103,108 18.9%   
No. of employees `0000.613.4 4.3%   
Total wages/salary Rs m1,1717,874 14.9%   
Avg. sales/employee Rs Th8,445.42,807.0 300.9%   
Avg. wages/employee Rs Th2,015.7585.8 344.1%   
Avg. net profit/employee Rs Th891.0329.0 270.8%   
INCOME DATA
Net Sales Rs m4,90737,732 13.0%  
Other income Rs m783577 135.7%   
Total revenues Rs m5,68938,309 14.9%   
Gross profit Rs m1236,901 1.8%  
Depreciation Rs m321,824 1.7%   
Interest Rs m16189 8.4%   
Profit before tax Rs m8585,465 15.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3401,042 32.6%   
Profit after tax Rs m5184,422 11.7%  
Gross profit margin %2.518.3 13.7%  
Effective tax rate %39.619.1 207.8%   
Net profit margin %10.611.7 90.0%  
BALANCE SHEET DATA
Current assets Rs m8,05523,778 33.9%   
Current liabilities Rs m1,85010,975 16.9%   
Net working cap to sales %126.433.9 372.7%  
Current ratio x4.42.2 200.9%  
Inventory Days Days45104 43.4%  
Debtors Days Days3466 51.4%  
Net fixed assets Rs m15020,368 0.7%   
Share capital Rs m123253 48.8%   
"Free" reserves Rs m7,46930,971 24.1%   
Net worth Rs m7,59231,224 24.3%   
Long term debt Rs m01,409 0.0%   
Total assets Rs m9,82445,507 21.6%  
Interest coverage x54.930.0 183.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 60.2%   
Return on assets %5.410.1 53.6%  
Return on equity %6.814.2 48.1%  
Return on capital %11.517.3 66.4%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m5817,308 0.3%   
Fx outflow Rs m1,3266,266 21.2%   
Net fx Rs m-1,26911,042 -11.5%   
CASH FLOW
From Operations Rs m-1,9434,923 -39.5%  
From Investments Rs m2,742-1,563 -175.4%  
From Financial Activity Rs m-298-1,832 16.3%  
Net Cashflow Rs m5011,528 32.8%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.4 17.5%  
FIIs % 1.6 25.3 6.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.4 123.6%  
Shareholders   41,647 36,892 112.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Nov 15, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS